Pfizer Establishes Durham, North Carolina, Clinical Manufacturing Campus
12/23/2021
According to company officials, the facility will be responsible for the manufacturing and analytical release of clinical supplies for Pfizer’s gene therapy and biologics portfolio. Approximately 40 employees will relocate from the company’s Chapel Hill site.
The Durham facility is part of an $800 million investment over the past six years to build three scalable, state-of-the-art gene therapy manufacturing facilities to support Pfizer’s continued investment in gene therapy research, development, and manufacturing.
“Gene therapy represents the next wave of innovation for patients living with rare diseases, for whom there are limited treatment options currently available,” said Paul Mensah, Vice President, BioTherapeutics Pharmaceutical Sciences at Pfizer. “Today represents the next step in strengthening Pfizer’s in-house gene therapy capabilities and underscores the unique ability, expertise, and resources we have to guide gene therapy through the entire development and manufacturing process and deliver this potentially life-changing technology to patients.”
Pfizer currently employs more than 3,600 people across its North Carolina sites, according to company officials. The new Durham location is an important part of Pfizer’s worldwide R&D network which includes locations in La Jolla, California; Boulder, Colorado; St Louis, Missouri; Pearl River, New York; Groton, Connecticut; and Cambridge and Andover, Massachusetts.
Project Announcements
Tate Plans Glasgow, Kentucky, Manufacturing Operations
10/28/2025
Electrolux Consumer Products Expands Kinston, North Carolina, Manufacturing Operations
10/28/2025
Canada-Based MST Rebar Plans Bladenboro, North Carolina, Manufacturing Operations
10/28/2025
Cardinal Biologicals Expands Cape Girardeau, Missouri, Operations
10/27/2025
Whirlpool Expands Clyde-Marion, Ohio, Production Operations
10/27/2025
Imperial Systems Plans Pennsylvania, Manufacturing Operations
10/27/2025
Most Read
-
2025’s Top States for Business: How the Winners Are Outpacing the Rest
Q3 2025
-
The Compliance Reckoning Is Here
Q3 2025
-
Around the Horn: Data Center Supply Chains — What's Next?
Q3 2025
-
Data Center Demand Stabilizes Amid Changing Market Forces
Q3 2025
-
How Consumer Trends Are Reshaping Food Facilities
Q3 2025
-
Powering the Next Generation of Projects
Q3 2025
-
First Person: Filter King’s Expansion Playbook
Q3 2025